Compare IVDA & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IVDA | MBIO |
|---|---|---|
| Founded | 2003 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7M | 4.1M |
| IPO Year | 2015 | 2023 |
| Metric | IVDA | MBIO |
|---|---|---|
| Price | $0.23 | $0.37 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 176.6K | 36.3K |
| Earning Date | 11-13-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 51.38 | ★ 98.99 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,468,279.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $405.45 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 132.98 | N/A |
| 52 Week Low | $0.21 | $0.37 |
| 52 Week High | $1.52 | $1.52 |
| Indicator | IVDA | MBIO |
|---|---|---|
| Relative Strength Index (RSI) | 37.90 | 29.78 |
| Support Level | $0.22 | N/A |
| Resistance Level | $0.31 | $0.56 |
| Average True Range (ATR) | 0.02 | 0.03 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 18.32 | 10.84 |
Iveda Solutions Inc offers smart city technologies globally, offering AI-driven video surveillance solutions and a robust suite of Internet of Things (IoT) platforms that power digital transformation for cities and commercial clients. The company offers AI-intelligent video search, smart utility, smart sensors, gateways, and trackers, and IoT platforms (Products). Geographically, the company operates in USA and Taiwan, majority of its revenue is generated from Taiwan.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.